Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? / Shahin Aghamiri, Keyvan Fallah Mehrjardi, Sasan Shabani, Mahsa Keshavarz-Fathi, Saeed Kargar, Nima Rezaei
Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nanomedicine - 14(2019), 15, Seite 2083- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aghamiri, Shahin [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (18 p) |
|---|
| doi: |
10.2217/nnm-2018-0379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001063383 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001063383 | ||
| 003 | DE-627 | ||
| 005 | 20230430081555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2018-0379 |2 doi | |
| 035 | |a (DE-627)KFL001063383 | ||
| 035 | |a (KFL)prod_FICIBQ_10.2217/nnm-2018-0379 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Aghamiri, Shahin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy? |c Shahin Aghamiri, Keyvan Fallah Mehrjardi, Sasan Shabani, Mahsa Keshavarz-Fathi, Saeed Kargar, Nima Rezaei |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (18 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Ovarian cancer is one of the most common causes of mortality throughout the world. Unfortunately, chemotherapy has failed to cure advanced cancers developing multidrug resistance (MDR). Moreover, it has critical side effects because of nonspecific toxicity. Thanks to specific silencing of oncogenes and MDR-associated genes, nano-siRNA drugs can be a great help address the limitations of chemotherapy. Here, we review the current advances in nanoparticle-mediated siRNA delivery strategies such as polymeric- and lipid-based systems, rigid nanoparticles and nanoparticles coupled to specific ligand systems. Nanoparticle-based codelivery of anticancer drugs and siRNA targeting various mechanisms of MDR is a cutting-edge strategy for ovarian cancer therapy, which is completely discussed in this review | ||
| 700 | 1 | |a Mehrjardi, Keyvan Fallah |e verfasserin |4 aut | |
| 700 | 1 | |a Shabani, Sasan |e verfasserin |4 aut | |
| 700 | 1 | |a Keshavarz-Fathi, Mahsa |e verfasserin |4 aut | |
| 700 | 1 | |a Kargar, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine |d London : Future Medicine Ltd, 2006 |g 14(2019), 15, Seite 2083- |h Online-Ressource |w (DE-627)KFL000006122 |w (DE-600)2254848-8 |w (DE-576)398100551 |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:15 |g pages:2083- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.2217/nnm-2018-0379 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 15 |h 2083- | ||